不可逆电穿孔(IRE):从前列腺癌实验室研究到临床治疗的叙述性综述
本文为叙述性综述,回顾不可逆电穿孔(IRE)从前列腺癌基础科学、体外与动物研究到临床队列的发展历程。已发表超过283例患者数据,控尿保留率91-100%、勃起功能保留率79-100%,野内复发率0%-33%;证据等级为IDEAL 2B,短期肿瘤学与功能结局令人鼓舞,但需长期数据验证后方可广泛推荐。
要点
- IRE通过直流电消融组织,用于选择性局限前列腺癌的局灶消融。
- 已发表>283例,控尿保留91-100%,勃起功能保留79-100%,野内复发0%-33%。
- 当前证据等级为IDEAL 2B,需长期数据验证后方可广泛推荐。
核心结论
- IRE是用于经仔细选择局限前列腺癌患者的新型局灶消融技术,短期肿瘤学与功能结局令人鼓舞。
- 在推荐广泛临床使用前,仍需长期数据验证该治疗。
研究设计与样本
- 叙述性综述,检索MEDLINE、EMBASE、PubMed和Google Scholar以识别IRE用于前列腺癌的历史视角与当前临床数据。
主要发现
- IRE发展遵循基础科学原理、体外数据、动物研究,现进入人类短至中期临床队列。
- 已发表IRE结果覆盖>283例患者,控尿(无尿垫)保留率91-100%,勃起功能保留率79-100%。
- 野内复发率范围为0%至33%。
关键数值与推荐
- 原发与挽救性前列腺癌IRE治疗的当前证据状态为IDEAL 2B。
临床怎么用
- IRE可用于经仔细选择的局限前列腺癌患者的局灶消融。
- 临床应用前应认识到现有证据为IDEAL 2B,需长期数据验证。
局限性
- 现有已发表队列仅报告短期肿瘤学与功能结局,需长期数据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Whilst whole-gland radical treatment is highly effective for prostate cancer control, it has significant impact on quality of life and is unnecessary 'over-treatment' in many men with screening-detected prostate cancer. Improvements in prostate biopsy and imaging have led to increased interest in partial gland ablation to reduce treatment-related morbidity. Several energies for focal ablation have been trialled. Irreversible electroporation (IRE) is a novel technology that ablates tissue by delivering direct current between electrodes. This narrative review documents the history of electroporation including its scientific basis, early data from pre-clinical animal studies, and contemporary clinical outcomes from the use of IRE in prostate cancer. METHODS: A literature search using the Medical Literature Analysis and Retrieval System Online (MEDLINE), the Excerpta Medica dataBASE (EMBASE), PubMed and Google Scholar was undertaken to identify historical perspectives and current clinical data relating to IRE for prostate cancer. RESULTS: The history of electroporation and its implementation as a prostate cancer treatment was following the basic scientific principles, in vitro data, then animal studies, and now short- to medium-term clinical cohorts in humans. The results of IRE on >283 patients have been published in several papers, with preserved rates of (pad-free) continence in 91-100% of men and preserved erectile function in 79-100% of men. In-field recurrence rates range from 0% to 33%. The current state of evidence for IRE for the treatment of primary and salvage prostate cancer is considered as Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) stage 2B. CONCLUSIONS: IRE is a new focal ablative technology for the treatment of localised prostate cancer in carefully selected men. Published cohorts report encouraging short-term oncological and functional outcomes; however, longer-term data are needed to validate this treatment before it can be recommended for widespread clinical use.
引用
- Blazevski A, Scheltema MJ, Amin A, et al. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. 2019. PMID: 31725935. doi:10.1111/bju.14951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。